2009-04-03 11:45:00 CEST

2009-04-03 11:46:13 CEST


REGULATED INFORMATION

English
CapMan - Changes board/management/auditors

Changes in CapMan Plc's management group



CapMan Stock Exchange Release 3 April 2009 12.45 p.m.

Head of CapMan Life Science, Senior Partner Jan Lundahl, B. Sc.
(Econ.) resigns from CapMan and leaves CapMan Plc's management group.
Deputy Head of CapMan Life Science, Partner Johan Bennarsten, M.Sc.
(Eng.), M.D., has been appointed as Head of CapMan Life Science
starting from 6 April 2009. Johan Bennarsten will report to CEO
Heikki Westerlund.

CapMan Life Science is one of CapMan's six investment areas. The
capital in CapMan's life science funds totaled EUR 88 million at the
end of 2008, and the funds have 12 portfolio companies. The capital
managed by CapMan totals EUR 3.4 billion and CapMan funds have
altogether over 60 companies and nearly 60 real estate targets in
their portfolios.

For more information, please contact:
Heikki Westerlund, CEO, CapMan Plc, tel.  +358 207 206 504 or +358
50 599 6580


CAPMAN PLC

Mari Reponen
Communications Director
Investor Services


DISTRIBUTION
Helsinki Stock Exchange
Principal media
www.capman.com


CapMan  www.capman.com
CapMan is one of the leading alternative asset managers in the Nordic
countries and Russia and manages private equity funds with
approximately EUR 3.4 billion in total capital. CapMan has six
investment areas (CapMan Buyout, CapMan Technology, CapMan Life
Science, CapMan Russia, CapMan Public Market and CapMan Real Estate),
and each of them has a dedicated team and funds. Altogether CapMan
employs over 140 people in Helsinki, Stockholm, Copenhagen, Oslo and
Moscow. CapMan was established in 1989 and its B shares are listed on
the Helsinki Stock Exchange since 2001.